- Home
- CRMT vs CELC Comparison
CRMT vs CELC Comparison
Compare CRMT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMT
- CELC
- Stock Information
- Founded
- CRMT 1981
- CELC 2011
- Country
- CRMT United States
- CELC United States
- Employees
- CRMT N/A
- CELC N/A
- Industry
- CRMT Other Specialty Stores
- CELC Medical Specialities
- Sector
- CRMT Consumer Discretionary
- CELC Health Care
- Exchange
- CRMT Nasdaq
- CELC Nasdaq
- Market Cap
- CRMT N/A
- CELC 327.3M
- IPO Year
- CRMT N/A
- CELC 2017
- Fundamental
- Price
- CRMT $49.61
- CELC $10.53
- Analyst Decision
- CRMT Hold
- CELC Strong Buy
- Analyst Count
- CRMT 2
- CELC 6
- Target Price
- CRMT $50.00
- CELC $30.17
- AVG Volume (30 Days)
- CRMT 61.0K
- CELC 195.9K
- Earning Date
- CRMT 06-17-2025
- CELC 05-14-2025
- Dividend Yield
- CRMT N/A
- CELC N/A
- EPS Growth
- CRMT N/A
- CELC N/A
- EPS
- CRMT 1.04
- CELC N/A
- Revenue
- CRMT $1,380,231,000.00
- CELC N/A
- Revenue This Year
- CRMT N/A
- CELC N/A
- Revenue Next Year
- CRMT $5.39
- CELC N/A
- P/E Ratio
- CRMT $46.31
- CELC N/A
- Revenue Growth
- CRMT N/A
- CELC N/A
- 52 Week Low
- CRMT $36.40
- CELC $7.58
- 52 Week High
- CRMT $72.26
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- CRMT 58.55
- CELC 51.41
- Support Level
- CRMT $46.44
- CELC $9.64
- Resistance Level
- CRMT $49.51
- CELC $11.66
- Average True Range (ATR)
- CRMT 1.68
- CELC 0.66
- MACD
- CRMT -0.03
- CELC -0.04
- Stochastic Oscillator
- CRMT 62.62
- CELC 44.06
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.